NEW YORK – Bio-Rad said on Thursday that it has acquired Ann Arbor, Michigan-based Celsee, which offers instruments and consumables for isolating, detecting, and analyzing single cells.
Financial terms of the acquisition were not disclosed.
Celsee's Genesis system enables users to isolate and analyze single cells for applications including cytometry, transcriptomics, multi-omics, rare-cell enrichment and enumeration, and immune monitoring.
The system can scale from hundreds of thousands to millions of cells for genomic and proteomic applications. It can also enrich for or monitor circulating tumor cells to determine disease progression and therapeutic response.
Celsee is currently embroiled in patent litigation with 10x Genomics, which has alleged patent infringement, unfair competition, false advertising, and related claims against Celsee in the US District Court for the District of Delaware. In late March, Celsee filed an answer and counterclaims to a second amended complaint by 10x.
Meanwhile, Herculese, California-based Bio-Rad itself remains involved in multiple patent lawsuits with 10x Genomics.